vs
Side-by-side financial comparison of BayCom Corp (BCML) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $25.9M, roughly 1.3× BayCom Corp). BayCom Corp runs the higher net margin — 26.5% vs -299.9%, a 326.4% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs 9.4%). Over the past eight quarters, BayCom Corp's revenue compounded faster (2.9% CAGR vs 1.4%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
BCML vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $34.1M |
| Net Profit | $6.9M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | -52.4% |
| Net Margin | 26.5% | -299.9% |
| Revenue YoY | 9.4% | 11.6% |
| Net Profit YoY | 12.1% | -232.0% |
| EPS (diluted) | $0.63 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $34.1M | ||
| Q3 25 | $25.7M | $44.0M | ||
| Q2 25 | $24.7M | $37.9M | ||
| Q1 25 | $24.3M | $30.0M | ||
| Q4 24 | $23.7M | $30.5M | ||
| Q3 24 | $25.6M | $38.8M | ||
| Q2 24 | $23.8M | $42.8M | ||
| Q1 24 | $24.5M | $33.1M |
| Q4 25 | $6.9M | $-102.2M | ||
| Q3 25 | $5.0M | $-33.1M | ||
| Q2 25 | $6.4M | $-37.3M | ||
| Q1 25 | $5.7M | $-23.5M | ||
| Q4 24 | $6.1M | $-30.8M | ||
| Q3 24 | $6.0M | $-32.1M | ||
| Q2 24 | $5.6M | $23.8M | ||
| Q1 24 | $5.9M | $-37.4M |
| Q4 25 | 36.6% | -52.4% | ||
| Q3 25 | 26.3% | -34.6% | ||
| Q2 25 | 35.3% | -64.3% | ||
| Q1 25 | 31.6% | -110.8% | ||
| Q4 24 | 34.2% | -102.4% | ||
| Q3 24 | 32.4% | -67.8% | ||
| Q2 24 | 31.9% | -65.7% | ||
| Q1 24 | 33.3% | -101.9% |
| Q4 25 | 26.5% | -299.9% | ||
| Q3 25 | 19.5% | -75.2% | ||
| Q2 25 | 25.8% | -98.2% | ||
| Q1 25 | 23.4% | -78.2% | ||
| Q4 24 | 25.9% | -100.8% | ||
| Q3 24 | 23.5% | -82.7% | ||
| Q2 24 | 23.6% | 55.6% | ||
| Q1 24 | 24.0% | -112.8% |
| Q4 25 | $0.63 | $-7.02 | ||
| Q3 25 | $0.46 | $-3.82 | ||
| Q2 25 | $0.58 | $-4.32 | ||
| Q1 25 | $0.51 | $-2.77 | ||
| Q4 24 | $0.55 | $-2.33 | ||
| Q3 24 | $0.54 | $-3.85 | ||
| Q2 24 | $0.50 | $-2.97 | ||
| Q1 24 | $0.51 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $-292.9M |
| Total Assets | $2.6B | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.5M | ||
| Q3 25 | — | $37.7M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $38.8M | ||
| Q4 24 | — | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | — | $84.8M | ||
| Q1 24 | — | $30.6M |
| Q4 25 | $338.6M | $-292.9M | ||
| Q3 25 | $334.3M | $-269.3M | ||
| Q2 25 | $330.6M | $-238.9M | ||
| Q1 25 | $329.3M | $-205.9M | ||
| Q4 24 | $324.4M | $-186.0M | ||
| Q3 24 | $321.7M | $-159.6M | ||
| Q2 24 | $315.3M | $-132.1M | ||
| Q1 24 | $314.2M | $-169.0M |
| Q4 25 | $2.6B | $108.4M | ||
| Q3 25 | $2.6B | $96.2M | ||
| Q2 25 | $2.6B | $104.9M | ||
| Q1 25 | $2.6B | $127.7M | ||
| Q4 24 | $2.7B | $164.4M | ||
| Q3 24 | $2.6B | $189.5M | ||
| Q2 24 | $2.6B | $214.0M | ||
| Q1 24 | $2.6B | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-11.8M |
| Free Cash FlowOCF − Capex | $30.1M | — |
| FCF MarginFCF / Revenue | 116.2% | — |
| Capex IntensityCapex / Revenue | 6.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-11.8M | ||
| Q3 25 | $7.3M | $-5.9M | ||
| Q2 25 | $6.4M | $-18.7M | ||
| Q1 25 | $9.3M | $-39.0M | ||
| Q4 24 | $30.4M | $-25.8M | ||
| Q3 24 | $9.6M | $-19.5M | ||
| Q2 24 | $7.7M | $-38.5M | ||
| Q1 24 | $5.1M | $-43.7M |
| Q4 25 | $30.1M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $9.1M | — | ||
| Q4 24 | $28.7M | $-25.9M | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $7.4M | — | ||
| Q1 24 | $3.9M | $-43.9M |
| Q4 25 | 116.2% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 121.1% | -84.7% | ||
| Q3 24 | 36.6% | — | ||
| Q2 24 | 31.2% | — | ||
| Q1 24 | 16.1% | -132.6% |
| Q4 25 | 6.7% | 0.0% | ||
| Q3 25 | 4.3% | 0.0% | ||
| Q2 25 | 3.0% | 0.0% | ||
| Q1 25 | 0.6% | 0.0% | ||
| Q4 24 | 7.2% | 0.2% | ||
| Q3 24 | 1.0% | 0.0% | ||
| Q2 24 | 1.0% | 0.0% | ||
| Q1 24 | 4.7% | 0.6% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | -1.62× | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
